Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)

NCT04053283 is registered in ClinicalTrials.gov with Akamis Bio as lead sponsor.

NCT NCT04053283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04053283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
Lead sponsor
Akamis Bio
Phase
Phase 1
Overall status
Completed
Start date
January 23, 2020
Completion date
December 20, 2023
Enrollment
186 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial tumor, metastatic cancer